Stockscreener 앱 받기
1.42
3.65%
0.05
시장 영업 전:
1.50
0.08
+5.63%
MAIA Biotechnology Inc 주식(MAIA)의 최신 뉴스
MAIA Biotechnology (MAIA) CEO awarded 800,000 stock options at $1.28 - Stock Titan
[Form 4] MAIA Biotechnology, Inc. Insider Trading Activity - Stock Titan
MAIA Biotechnology (MAIA) grants 30,000 stock options to finance head - Stock Titan
EPS Watch: How do insiders feel about MAIA Biotechnology IncMarket Movement Recap & Safe Capital Growth Plans - baoquankhu1.vn
Aug Drivers: How does MAIA Biotechnology Inc compare to its peersMarket Risk Summary & Real-Time Sentiment Analysis - baoquankhu1.vn
Value Recap: Is MAIA Biotechnology Inc trading at a discountLayoff News & Free Safe Capital Growth Stock Tips - baoquankhu1.vn
Short Covering: Is MAIA Biotechnology Inc stock forming a cup and handle2026 Sector Review & Free Reliable Trade Execution Plans - baoquankhu1.vn
Earnings Report: Is MAIA Biotechnology Inc stock forming a cup and handle - baoquankhu1.vn
Day Trade: What are the future prospects of MAIA Biotechnology IncBond Market & AI Optimized Trade Strategies - baoquankhu1.vn
Earnings Recap: Is MAIA Biotechnology Inc in a long term uptrend2026 Volume & Daily Risk Controlled Trade Plans - baoquankhu1.vn
MAIA Biotechnology Raises $33M to Fully Fund Pivotal Phase 3 Trial of Ateganosine for Advanced NSCLC Treatment - Minichart
MAIA Fully Funds Pivotal Phase 3 THIO-104 NSCLC Trial - TipRanks
MAIA Biotechnology Expects Recent $33 Million Capital Raise to Fully Fund Ongoing Pivotal Phase 3 Trial of Novel Telomere-Targeting Anticancer Therapy - The Manila Times
MAIA Biotechnology says $33M raise should fully fund pivotal Phase 3 trial of ateganosine - TradingView — Track All Markets
MAIA (NYSE: MAIA) uses $33M raise to fund Phase 3 lung cancer study - Stock Titan
$33M gives MAIA runway to finish late-stage lung cancer study - Stock Titan
MAIA Biotechnology (NYSE American: MAIA) plans 2026 virtual shareholder meeting, pay vote - Stock Titan
MAIA Biotechnology Awards Executive Bonuses After Successful Financing - TipRanks
MAIA Biotechnology (NASDAQ: MAIA) director receives 27,258 stock options at $1.40 - Stock Titan
MAIA Biotechnology (MAIA) awards director 27,907 options at $1.40 - Stock Titan
MAIA (MAIA) director receives grant of 27,258 stock options - Stock Titan
MAIA Biotechnology (MAIA) director granted 33,748 stock options - Stock Titan
MAIA (MAIA) director receives 28,556 stock options at $1.40 strike - Stock Titan
MAIA Biotechnology (MAIA) awards cash bonuses after recent capital raise - Stock Titan
Noble Financial Maintains MAIA Biotechnology(MAIA.US) With Buy Rating, Maintains Target Price $14 - Moomoo
Bond Watch: How does MAIA Biotechnology Inc compare to its peersEarnings Recap Report & Growth-Oriented Investment Plans - baoquankhu1.vn
MAIA Highlights Promising Phase 2 NSCLC Survival Outcomes - TipRanks
Treasury Yields: Is now the right time to enter MAIA Biotechnology Inc2026 Price Momentum & Free Real-Time Volume Trigger Notifications - baoquankhu1.vn
MAIA Biotechnology reports >2-year overall survival for 8 NSCLC patients in Phase 2 THIO-101 - TradingView — Track All Markets
MAIA Biotechnology Reports Overall Survival Exceeding Two Years for Eight Patients in Ongoing Phase 2 Clinical Trial in Non-Small Cell Lung Cancer - The Manila Times
Maia Biotechnology Reports Overall Survival Exceeding Two Years For Eight Patients In Ongoing Phase 2 Clinical Trial In Non-Small Cell Lung Cancer - TradingView
Eight MAIA (NYSE: MAIA) NSCLC patients top two-year survival on Phase 2 regimen - Stock Titan
After prior treatment failed, 8 lung cancer patients lived past 2 years - Stock Titan
Short Interest in MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) Drops By 26.2% - MarketBeat
MAIA PE Ratio & Valuation, Is MAIA Overvalued - Intellectia AI
MAIA Showcases THIO-101 NSCLC Data at ELCC 2026 - The Globe and Mail
MAIA Biotechnology presents THIO-101 poster showing sustained responses in relapsed NSCLC - TradingView
MAIA Biotechnology (NYSE American: MAIA) presents ELCC 2026 trial poster - Stock Titan
Diamond Equity Research Releases Update Note on MAIA Biotechnology, Inc. (NYSE: MAIA) - finance.yahoo.com
MAIA Biotechnology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - MarketScreener
MAIA Biotechnology, Inc. 2025 Annual 10-K SEC Filing Overview: Private Placements, Warrants, and Equity Transactions - Minichart
MAIA Biotechnology (NYSEAMERICAN:MAIA) Releases Quarterly Earnings Results, Beats Estimates By $0.05 EPS - marketbeat.com
MAIA Biotechnology 10-K: Operating loss $24.27M, Net loss $22.40M; Cash $8.66M - TradingView
MAIA: Advanced clinical pipeline and $33M capital raise position company for pivotal 2026 milestones - TradingView
MAIA Biotechnology (MAIA) advances ateganosine with Fast Track and Phase 3 NSCLC trial - Stock Titan
Market Review: Will MAIA Biotechnology Inc outperform small cap indexes2026 Market WrapUp & AI Powered Buy and Sell Recommendations - baoquankhu1.vn
Fundamentals Check: What are the future prospects of MAIA Biotechnology IncPortfolio Update Report & AI Driven Price Forecasts - baoquankhu1.vn
Short Interest in MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) Expands By 17.9% - MarketBeat
MAIA Biotechnology (MAIA) Expected to Announce Quarterly Earnings on Friday - Defense World
MAIA Biotechnology (NYSEAMERICAN:MAIA) Stock Price Up 0.7%Still a Buy? - MarketBeat
MAIA Earnings History & Surprises | EPS & Revenue Results | MAIA BIOTECHNOLOGY INC (NYSEARCA:MAIA) - ChartMill
Is the Market Bullish or Bearish on MAIA Biotechnology Inc? - Sahm
MAIA Biotechnology Announces Closing of $30 Million Underwritten Public Offering of Common Stock - Sahm
Diamond Equity Research Releases Update Note on MAIA Biotechnology, Inc. (NYSE: MAIA) - GlobeNewswire Inc.
MAIA Biotechnology Completes $30 Million Public Stock Offering - TipRanks
Maia Biotechnology Inc enters underwriting agreement with Konik Capital PartnersSEC filing - marketscreener.com
Maia Biotechnology Inc Enters Underwriting Agreement With Konik Capital PartnersSEC Filing - TradingView
MAIA Biotechnology (NYSE American: MAIA) closes $30M common stock raise - Stock Titan
MAIA Biotechnology Prices $30 Million Offering of 20 Million Shares at $1.50 - TradingView
2.69%
0.25%
자본화:
|
볼륨(24시간):